Company profile

MBX Biosciences

MBX Biosciences has raised $216 million across three funding rounds, supported by leading biotech investors including Frazier Healthcare Partners, Orbimed, Wellington, RA Capital Management, Deep Track Capital, and others. The company’s funding history includes a Series A of $34.6M, Series B of $115M, and a Series C of $63.5M, backing its mission to develop precision therapies for rare endocrine disorders. With strong investor confidence and a focused drug development pipeline, MBX Biosciences continues to expand clinical programs and strengthen its leadership in endocrine therapeutics.

Back to profiles

Quick facts

Total funding: $216 million

Notable investors

Frazier Healthcare Partners
Orbimed
Wellington
RA Capital Management
Deep Track Capital

Reach buyers like MBX Biosciences on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like MBX Biosciences
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like MBX Biosciences.

The 14-day trial ships every feature, no card required.

Start free →